• Introduction to Cancer Therapy
• 46 min
  1. Development of a cancer drug

  • Prof. Martin Edelman
• Use of Novel "Targeted" Agents in Combination with Classical Cytotoxic Chemotherapy
• 35 min
  2. Small molecule inhibitors of receptor tyrosine kinases

  • Dr. Daniela Krause
• Innovative Strategies of Clinical Drug Development
• 46 min
  3. Phase II trials

  • Dr. Patricia Tang
• 33 min
  4. Surrogate endpoints of efficacy

  • Prof. Maurie Markman
• Biomarkers in Oncology: Rationale Development and Current Use
• 27 min
  5. Biomarkers in oncology: overview

  • Prof. Joe Duffy
• 55 min
  6. Genetic polymorphism of thiopurine methyltransferase and thiopurine therapy: from molecular genetics to clinical medicine

  • Dr. William Evans
• Archived Lectures *These may not cover the latest advances in the field
• 42 min
  7. Emerging trends in phase II trial design

  • Dr. Patricia Tang
• 36 min
  8. EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients

  • Prof. Fred Hirsch
• 36 min
  9. Therapy in cancer 2008: quo vadis?

  • Dr. Jeffrey Clark
• 34 min
  10. Changing paradigms in anticancer drug development: inhibiting angiogenesis in colorectal cancer

  • Prof. David Kerr
• 32 min
  11. Phase III trials

  • Prof. Martin Edelman
• 43 min
  12. Germline pharmacogenomics as a tool to individualize therapy in breast cancer

  • Dr. David Flockhart
• 33 min
  13. Gene profiling in breast cancer

  • Dr. Enrique Espinosa
• 31 min
  14. UGT1A1 polymorphisms and irinotecan toxicity in colorectal cancer patients

  • Prof. Tae Won Kim
• 28 min
  15. Principles of cancer treatment: surgery, radiotherapy, chemotherapy, immunotherapy

  • Dr. Theodore Yaeger
• 25 min
  16. Understanding cancer trends

  • Prof. Michael Thun
• 54 min
  17. Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

  • Dr. Tracey Evans
• 40 min
  18. Phase I study design for non-cytotoxic agents

  • Dr. Wendy Parulekar
• 36 min
  19. Early detection of lung cancer

  • Prof. Stephen Lam
• 60 min
  20. Cytotoxic chemotherapy

  • Dr. Michael Sawyer

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Alkylating agents
4. Classification of alkylating agents
5. Alkylating agents: electrophilic side chains
6. Categories of alkylating agents
7. Nitrogen mustards
8. Mechlorethamine (Nitrogen mustard)
9. Melphalan (L-phenylalanine mustard) (1)
10. Melphalan (L-phenylalanine mustard) (2)
11. Cyclophosphamide/Ifosfamide (1)
12. Cyclophosphamide/Ifosfamide (2)
13. The effect of cyclophosphamide/Ifosfamide
14. Chloroethyl nitrosoureas
15. The use of chloroethyl nitrosoureas in the clinic
16. Dacarbazine (DTIC)
17. Temozolomide
18. Mitomycin C
19. Trabectedin
20. Cisplatin
21. Types of platinum drugs
22. Cisplatin: mechanism of action
23. Cisplatin DNA binding
24. Various forms of adducts
25. Nucleotide excision repair
26. Scheme of ERCC1 pathway
27. High mobility group proteins
28. Mismatch repair
29. Scheme of the mismatch repair pathway
30. Resistance to platiunm drugs by MMR activity
31. Platinum uptake
32. Cisplatin efflux transporters
33. Copper transporters
34. Cisplatin vs. Carboplatin vs. Oxaliplatin
35. Neuropathy
36. Oxaliplatin neuropathy
37. Tubulin/microtubule structure and function
38. Microtubule assembly
39. Microtubule formation is a dynamic process
40. Targeting Tubulins
41. Vinca alkaloids
42. Comparing features of vinca alkaloids
43. Vinca alkaloids toxicities
44. Taxanes
45. Comparing features of taxanes
46. Paclitaxel and docetaxel toxicities
47. Novel taxanes
48. Epothilones
49. Comparing features of epothilones
50. Antimetabolites
51. Antifolates
52. Chemical structure of folic acid and methotrexate
53. Modern antifolates
54. Basic pharmacology of antifolates
55. Pemetrexed
56. Basic pharmacology of pemetrexed
57. Renal dysfunction
58. Risk factors
59. 5FU pharmacology
60. Nucleosides
61. Capecitabine
62. Cytarabine
63. Gemcitabine
64. Purine analogues
65. Fludarabine
66. Nucleoside transporters
67. Survival in relation to hENT1 expression
68. Definition of Topoisomerases
69. Classes of Topoisomerases
70. Topoisomerase inhibitors (1)
71. Topoisomerase inhibitors (2)
72. Classes of TI
73. Topoisomerase I inhibitors
74. Camptothecin
75. Irinotecan
76. Irinotecan special precautions
77. Topotecan
78. Topotecan special precautions
79. Topoisomerase II inhibitors
80. Etoposide
81. Etoposide special precautions
82. Tenoposide
83. Tenoposide special precautions
84. Anthracyclines
85. Anthracycline mechanism of action
86. Anthracycline pharmacokinetics
87. Anthracycline toxicities
88. Anthracycline cardiotoxicity
89. Thank you

Topics Covered

• Alkylating agents
• Nitrogen mustards
• Nucleotide excision repair
• Mismatch repair
• Platinum compounds
• Tubulin acting agents
• Tubulin/microtubule structure and function
• Vinca alkaloids
• Antimetabolites
• Anthracyclines
• Nucleoside transporters
• Topisomerase inhibitors

Links

Series:

• Cancer Therapy

Categories:

• Biochemistry
• Cancer
• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on June 28, 2009
• Archived on May 28, 2025

Financial Disclosures

• Dr. Michael Sawyer has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.